Literature DB >> 20826613

Evaluation of clumping factor A binding region A in a subunit vaccine against Staphylococcus aureus-induced mastitis in mice.

Rui Gong1, Changmin Hu, Haiyang Xu, Aizhen Guo, Huanchun Chen, Guangzhi Zhang, Lei Shi.   

Abstract

The present study evaluated the potential of recombinant binding region A of clumping factor A (rClfA-A) to be an effective component of a vaccine against mastitis induced by Staphylococcus aureus in the mouse. rClfA-A and inactivated S. aureus were each emulsified in Freund's adjuvant, mineral oil adjuvant, and Seppic adjuvant; phosphate-buffered saline was used as a control. Seven groups of 12 mice each were immunized intraperitoneally three times at 2-week intervals. The titers of IgG and subtypes thereof (IgG1 and IgG2a) in the rClfA-A-immunized group were more than 1,000-fold higher than those in the killed-bacteria-immunized group (P < 0.01). Of the three adjuvants used, mineral oil adjuvant induced the highest antibody levels for both antigens (P < 0.001). Furthermore, the anti-rClfA-A antibody capacities for bacterial adhesion and opsonizing phagocytosis were significantly greater in the rClfA-A-immunized group than in the killed-bacteria-immunized group (P < 0.05). Lactating mice immunized with either rClfA-A or inactivated vaccine were challenged with S. aureus via the intramammary route. The numbers of bacteria recovered from the murine mammary glands 24 h after inoculation were significantly lower in the rClfA-A group than in the killed-bacteria-immunized group (P < 0.001). Histologic examination of the mammary glands showed that rClfA-A immunization effectively preserved tissue integrity. Thus, rClfA-A emulsified in an oil adjuvant provides strong immune protection against S. aureus-induced mastitis in the mouse.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826613      PMCID: PMC2976091          DOI: 10.1128/CVI.00162-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

Review 1.  Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications.

Authors:  G N Ferreira; G A Monteiro; D M Prazeres; J M Cabral
Journal:  Trends Biotechnol       Date:  2000-09       Impact factor: 19.536

2.  Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

Authors:  S K Kim; G Ragupathi; C Musselli; S J Choi; Y S Park; P O Livingston
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

3.  DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus.

Authors:  Eric Brouillette; Pierre Lacasse; Lulzim Shkreta; Jérome Bélanger; Gilles Grondin; Moussa S Diarra; Sylvie Fournier; Brian G Talbot
Journal:  Vaccine       Date:  2002-05-22       Impact factor: 3.641

4.  Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant.

Authors:  E Josefsson; O Hartford; L O'Brien; J M Patti; T Foster
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

5.  Identification of residues in the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding.

Authors:  O M Hartford; E R Wann; M Höök; T J Foster
Journal:  J Biol Chem       Date:  2000-10-23       Impact factor: 5.157

6.  Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle.

Authors:  T Tollersrud; L Zernichow; S R Andersen; K Kenny; A Lund
Journal:  Vaccine       Date:  2001-07-16       Impact factor: 3.641

7.  Cell subpopulations and cytokine expression in cow milk in response to chronic Staphylococcus aureus infection.

Authors:  C Riollet; P Rainard; B Poutrel
Journal:  J Dairy Sci       Date:  2001-05       Impact factor: 4.034

8.  Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat.

Authors:  A Rennermalm; Y H Li; L Bohaufs; C Jarstrand; A Brauner; F R Brennan; J I Flock
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

9.  Lactoferrin against Staphylococcus aureus Mastitis. Lactoferrin alone or in combination with penicillin G on bovine polymorphonuclear function and mammary epithelial cells colonisation by Staphylococcus aureus.

Authors:  Moussa S Diarra; Denis Petitclerc; Elaine Deschênes; Nolwenn Lessard; Gilles Grondin; Brian G Talbot; Pierre Lacasse
Journal:  Vet Immunol Immunopathol       Date:  2003-09-15       Impact factor: 2.046

Review 10.  Macrophage inflammatory protein-1.

Authors:  M Maurer; E von Stebut
Journal:  Int J Biochem Cell Biol       Date:  2004-10       Impact factor: 5.085

View more
  13 in total

1.  Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants.

Authors:  Rebecca A Brady; Christopher P Mocca; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

Review 2.  Development of a vaccine against Staphylococcus aureus.

Authors:  Brad Spellberg; Robert Daum
Journal:  Semin Immunopathol       Date:  2011-11-14       Impact factor: 9.623

3.  Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis.

Authors:  N Misra; T F Wines; C L Knopp; R Hermann; L Bond; B Mitchell; M A McGuire; J K Tinker
Journal:  Vaccine       Date:  2018-05-05       Impact factor: 3.641

4.  Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice.

Authors:  Haiyang Xu; Changmin Hu; Rui Gong; Yingyu Chen; Ningning Ren; Ganwen Xiao; Qian Xie; Minmin Zhang; Qin Liu; Aizhen Guo; Huanchun Chen
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

Review 5.  Staphylococcus aureus Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions.

Authors:  H A Crosby; J Kwiecinski; A R Horswill
Journal:  Adv Appl Microbiol       Date:  2016-08-04       Impact factor: 5.086

6.  Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA-IsdB-Hlg as a vaccine candidate.

Authors:  Somayeh Delfani; Ashraf Mohabati Mobarez; Abbas Ali Imani Fooladi; Jafar Amani; Mohammad Emaneini
Journal:  Med Microbiol Immunol       Date:  2015-07-09       Impact factor: 3.402

7.  Evaluation of genetically inactivated alpha toxin for protection in multiple mouse models of Staphylococcus aureus infection.

Authors:  Rebecca A Brady; Christopher P Mocca; Ranjani Prabhakara; Roger D Plaut; Mark E Shirtliff; Tod J Merkel; Drusilla L Burns
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

8.  Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.

Authors:  Jack Levy; Laurent Licini; Edwige Haelterman; Philippe Moris; Pascal Lestrate; Silvia Damaso; Pascale Van Belle; Dominique Boutriau
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Immunisation With Immunodominant Linear B Cell Epitopes Vaccine of Manganese Transport Protein C Confers Protection against Staphylococcus aureus Infection.

Authors:  Hui-Jie Yang; Jin-Yong Zhang; Chao Wei; Liu-Yang Yang; Qian-Fei Zuo; Yuan Zhuang; You-Jun Feng; Swaminath Srinivas; Hao Zeng; Quan-Ming Zou
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

10.  Identification and screening of effective protective antigens for channel catfish against Streptococcus iniae.

Authors:  Yajun Wang; Erlong Wang; Yang He; Kaiyu Wang; Qian Yang; Jun Wang; Yi Geng; Defang Chen; Xiaoli Huang; Ping Ouyang; Weimin Lai; Cunbin Shi
Journal:  Oncotarget       Date:  2017-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.